Ionis Pharmaceuticals, Inc. today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients with Huntington's disease (HD).

Earlier today, Ionis Pharmaceuticals announced the enrollment completion in its Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRs in Huntington’s Disease (HD) patients.

Approval represents the first new treatment option for chorea associated with Huntington’s disease in nearly a decade

The Hereditary Neurological Disease Centre is a free-standing, non-profit organization. We often use the short version-HNDC- and this has apparently brought some confusion with the national HD organization, Huntington’s Disease Society of America (HDSA). 

A drug which appears to reverse Huntington’s disease is being trialled in humans after proving successful in monkeys and mice.

People with Huntington disease experienced improvements in chorea while taking deutetrabenazine (SD-809) compared to placebo, according to a paper published today in the Journal of the American Medical Association (JAMA).